Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Clinical trial NCT06093061 · RECRUITING
Trial details
- NCT number
- NCT06093061
- Sponsor
- National Cancer Centre, Singapore
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-03
- Primary completion
- 2028-10-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.